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Phospho-ERK Staining Is a Poor Indicator of the
Mutational Status of BRAF and NRAS in Human
Melanoma
Roland Houben1, Claudia S. Vetter-Kauczok1, Sonja Ortmann1, Ulf R. Rapp2, Eva B. Broecker1 and
Juergen C. Becker1
Mutated BRAF and NRAS are suspected to contribute to melanomagenesis by activation of extracellular signal-
regulated kinase (ERK). To test this notion, we analyzed the presence of phosphorylated ERK1/2 in 170
melanomas with established NRAS/BRAF mutational status and well-documented clinical follow-up by
immunohistochemistry. Several notable observations were obtained: (i) phospho-ERK staining was very
heterogeneous within the tumor; (ii) in most cases, ERK was phosphorylated in only a minority of tumor cells;
(iii) the percentage of phospho-ERK-positive cells was not correlated with the mutational status of NRAS and/or
BRAF; (iv) the Raf kinase inhibitor protein (RKIP) was expressed homogeneously in virtually all melanoma
samples not reflecting the inhomogeneity of phospho-ERK; and, finally, (v) neither the portion of phospho-ERK-
positive tumor cells nor the RKIP staining intensity showed any correlation to the clinical course of the patients.
Furthermore, the ability of BRAF mutant melanoma cells to downregulate mitogen-activated protein kinase
activation was shown in melanoma cell lines cultured at high densities or under nonadherent conditions. Our
findings suggest that mitogen-activated protein kinase (MAPK) activity is subject to regulation even in BRAF/
NRAS mutant melanoma cells and that high MAPK pathway signaling may be important only in distinct subsets
of tumor cells.
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INTRODUCTION
Malignant melanoma has very poor prognosis when metas-
tasized and fails to respond to currently available therapies
(Tarhini and Agarwala, 2006). Recent reports on aberrant
signal transduction, particularly within the mitogen-activated
protein (MAP) kinase pathway, opened new avenues for
targeted molecular therapy of melanoma (Becker et al., 2006).
Clinical trials evaluating the low-molecular-weight Raf kinase
inhibitor Sorafenib (BAY 43-9006) for therapeutic efficacy in
melanoma have been started; however, they have had poor
outcomes so far, at least in monotherapy (Eisen et al., 2006).
Melanoma was among the cancers chosen to test the
efficiency of Sorafenib, because the most frequent molecular
event associated with melanomagenesis is a mutation of the
BRAF gene. Raf proteins are on top of the classical
cytoplasmic kinase cascade module (Raf–MEK–extracellular
signal-regulated kinase (ERK)), which transmits growth signals
from activated Ras at the plasma membrane to transcription
factors in the nucleus and other cellular targets. Other than
BRAF, which is found to be mutated with a mean frequency
of 46% in 2,338 melanoma samples analyzed (Catalogue of
Somatic Mutations in Cancer (COSMIC), http://www.sanger.
ac.uk/genetics/CGP/cosmic/), additional activators of the
MAP kinase cascade have been described to be altered; for
example, according to the COSMIC database, NRAS is
mutated in 19% of melanoma.
The fact that somatic mutations in BRAF and NRAS are
mutually exclusive suggests that both alterations contribute to
oncogenesis via the same pathway. Although Raf proteins are
known to have additional cellular targets (Baccarini, 2005), it
is still generally anticipated that Raf is oncogenic via the MAP
kinase pathway (Rapp et al., 2006). All BRAF mutations
detected in tumors until now induce activation of the MAP
kinase pathway in cell culture experiments, although a
minor fraction of BRAF mutants demonstrated a decreased
in vitro kinase activity toward MEK (Houben et al., 2004;
Wan et al., 2004). These mutants, however, can still induce
ERK phosphorylation indirectly via a mechanism that
involves 14-3-3 proteins as well as heterodimerization and
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transactivation of CRAF (Garnett et al., 2005). Moreover,
melanoma cell lines bearing BRAF mutations are particularly
sensitive to MEK inhibition (Solit et al., 2006). The fact that
this property distinguishes BRAF-mutated melanoma cell
lines from those with NRAS mutations supports the assump-
tion that NRAS and BRAF mutations, at least in established
cell lines, are not completely equivalent. Indeed, it is known
that Ras signals through further pathways, including AKT
(Giehl, 2005), and introduction of activated NRAS in
melanocytes causes a switch from signaling through BRAF
to signal transduction through CRAF (Dumaz et al., 2006).
It should be noted, however, that most of these notions
were established in vitro by means of long-term cultured
melanoma cell lines. Consequently, to further evaluate the
role of the MAP kinase pathway activity in melanoma, we
scrutinized ERK phosphorylation in situ in a substantial series
of primary and metastatic melanomas with known BRAF and
NRASmutational status and well-documented clinical course
of the respective patients. Surprisingly, this analysis revealed
the absence of detectable ERK phosphorylation in the
majority of tumor cells. Strikingly, the presence of phospho-
ERK-positive cells did not correlate at all with the presence of
activating BRAF and/or NRAS mutations.
RESULTS
ERK phosphorylation is very heterogeneous and frequently
virtually undetectable in melanoma
To elucidate the consequences of activating BRAF or NRAS
mutations on the activation status of the MAP kinase
pathway, we analyzed 98 vertical growth phase and 72
metastatic melanomas for which the BRAF exons 11 and 15
and the NRAS exons 1 and 2 had been sequenced before
(Houben et al., 2004). Table 1 summarizes the mutation data
of the analyzed tumors. In 40.0% of the tumors of this series,
BRAFmutations were present, 95% of which were changes of
valine 600 to a hydrophilic residue; 21.2% of the tumors
harbored activating NRAS mutations. In none of the samples
were mutations in both genes detected. Tissue sections of
these tumors, as well as of an additional 35 primary tumors in
radial growth phase, were analyzed for the presence of
phosphorylated ERK protein by means of two different
phosphospecific mAbs. These were the clone 20G11, which
is currently recommended for immunohistochemistry (IHC)
by the manufacturer (Cell Signaling Technology, Beverly,
MA), and the clone E10, which was initially recommended
for IHC when this project was started. For both of these Abs,
similar staining patterns were observed; that is, positive
signals for phospho-ERK markedly differed between tumors
but were also very heterogeneous within most of the
individual lesions (Figure 1). Although there were a few
cases in which ERK phosphorylation was detectable in
virtually all tumor cells (Table 2; Figure 1a and b), in the
majority of tissue sections only a limited portion of the tumor
cells stained positive for phospho-ERK. These heavily stained
cells were located either as focal islands (Figure 1f and g) or
as single cells (Figure 1c–e) within a majority of surrounding
phospho-ERK-negative tumor cells (Table 2). However,
the most frequent pattern observed with both Abs in
approximately 50% of the samples analyzed (Table 2) is
shown in Figure 1h: it is actually characterized by an almost
complete absence of ERK phosphorylation in the tumor cells
(Table 2). Interestingly, in several (n¼ 4) of the tumors, which
were characterized by single phospho-ERK-positive cells,
these cells showed mitotic structures (Figure 1d). Notably, in
tumors that lacked phospho-ERK-positive tumor cells, we
nevertheless detected phospho-ERK-positive stroma cells (for
example, endothelial cells (Figure 1e) or macrophages
(arrows in Figure 1h) serving as internal positive controls.
To further confirm that handling of the tumor samples was
suitable to preserve protein phosphorylation, we stained 20 of
the samples that lacked phospho-ERK-positive tumor cells for
phosphorylated retinoblastoma protein. In all cases, phospho-
retinoblastoma protein was easily detected in part of the
tumor cells (data not shown).
Notably, the lack of ERK phosphorylation was not due to
low expression of ERK protein, as staining for total ERK1/2 in
primary and metastatic melanomas demonstrated that it was
generally strongly and homogeneously expressed. Indeed,
ERK1/2 staining was more prominent in tumor cells than in
infiltrating stromal cells (Table 2 and Figure 1j).
Subcellular localization of phospho-ERK in melanoma cells
Using the antibody (Ab) E10, most of the phospho-ERK-
positive cells displayed predominantly cytoplasmic staining,
whereas only in a minor fraction did the nucleus stain
positive (Figure 1i). In contrast, with the Ab 20G11, nuclear
staining was observed more frequently (Figure 1b), and in all
tumors with a considerable fraction of phospho-ERK-positive
tumor cells, at least a part of the positive cells also showed
nuclear staining. Upon stimulation of resting cells, ERK
Table 1. Absolute and relative numbers of activating
BRAF and NRAS mutations detected in the series of
tumor samples also analyzed for ERK phosphorylation
NRAS BRAF NRAS or BRAF
Primary VGP melanomas
Sequenced 98 98 98
Mutation 18 36 54
% 18.4 36.7 55.1
Metastases
Sequenced 72 72 72
Mutation 18 32 50
% 25.0 44.4 69.4
All tumors
Sequenced 170 170 170
Mutation 36 68 104
% 21.2 40.0 60.5
ERK, extracellular signal-regulated kinase; VGP, vertical growth phase.
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phosphorylation has been reported to be accompanied by
nuclear translocation and part of the MAPK target proteins are
transcription factors (Chen et al., 2001). To analyze the
subcellular distribution of phospho-ERK in melanoma cells
under steady-state conditions, we performed Western blot
analysis with cytoplasmic and nuclear fractions derived from
three melanoma cell lines. Notably, under these conditions,
the majority of phosphorylated ERK was detected in the
cytoplasmic fraction, confirming the pattern found by IHC
(Figure 3c).
The proportion of phospho-ERK-positive cells is not correlated
with the presence of activating BRAF and/or NRAS mutations
In cell culture experiments, it was repeatedly demonstrated
that activating mutations of Raf or Ras lead to constitutive
growth-factor-independent activation of the MAP kinase
pathway (Zebisch and Troppmair, 2006). Therefore, one
might expect a generally increased ERK phosphorylation in
tumors carrying activating mutations in these genes.
However, the blatant inhomogeneity between some cells
displaying strong ERK phosphorylation and many others with
a b c
d e f
g h i
j k l
Figure 1. ERK phosphorylation and RKIP expression in melanoma. (a–e) The micrographs show immunohistochemistry for ERK phosphorylated at residues
Thr202 and Tyr204 using the antibody (Ab) clone 20G11. (f–i) Phospho-ERK was detected by the use of the Ab clone E10. (j) Total ERK staining and (k and l) RKIP
expression.
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a very weak or absent signal was observed for BRAF/NRAS wt
as well as BRAF/NRAS mutant tumors (Figure 1). Moreover,
when the proportion of phospho-ERK-positive cells was
compared between tumors with BRAF mutation and tumors
without BRAF mutation or between tumors with BRAF or
NRAS mutation and tumors without such alterations, no
significant differences could be detected (Figure 2). This was
irrespective of whether the Ab 20G11 or E10 was used for
detection of phospho-ERK.
In BRAF mutant melanoma cell lines, ERK phosphorylation is
still subject to regulation
The absence of detectable ERK phosphorylation in many
melanomas carrying activated mutations in BRAF suggests
that these cells have an intrinsic mechanism capable of
shutting down signaling on the relatively short stretch
between B-Raf and ERK1/2. To analyze whether activity of
the MAP kinase pathway can actually be regulated in BRAF
mutant melanoma cells, we made use of the cell lines
Skmel28, Mel2A, and FM88, which are homo- or hemi-
zygous for V600E, heterozygous for V600E, and homo- or
hemizygous for V600K, respectively. The cell lines were
seeded at different cell densities ranging from very low to
completely confluent. Twenty-four hours later, cells were
harvested and the level of ERK phosphorylation was
determined by Western blot. In fact, we observed for all
three cell lines a partial or complete loss of phospho-ERK
when cells were harvested at high cell densities (Figure 3a).
This indicates that mutation of the BRAF gene in melanoma
cells does not lead to a completely uncontrolled MAP kinase
pathway activity but that ERK phosphorylation is still subject
to regulation, for example, by high-density inhibition. Among
the extracellular factors that can influence MAP kinase
pathway activity is engagement of integrins (Juliano et al.,
2004). When the three BRAF mutant cell lines were cultured
in coated plates, not allowing adherence to the plastic, we
observed a partial reduction in ERK phosphorylation (Figure 3b).
This observation confirms the ability of melanoma cells to
regulate the activity of the MAP kinase cascades, even in the
presence of constitutive active BRAF.
Raf kinase inhibitor protein is homogeneously expressed in both
primary and metastatic melanoma
The Raf kinase inhibitor protein (RKIP) binds to Raf and MEK
and thereby may interfere with interactions between these
two proteins; for example, preventing activation of MEK by
Raf (Yeung et al., 1999). To answer the question as to whether
RKIP may be involved in silencing of the MAP kinase
pathway in melanoma cells, particularly in melanoma with
activating BRAF or NRAS mutations, we analyzed our series
of tumor samples for RKIP protein expression. This analysis
revealed a strong and homogeneous RKIP expression in all
melanoma samples, in most cases in all tumor cells,
irrespective of whether it was a primary tumor or a metastasis
(Table 2). In fact, RKIP staining clearly distinguished between
tumor cells and surrounding or infiltrating stroma cells, as
only a minor fraction of stromal cells (generally in all
analyzed tumor samples less than 10%) expressed RKIP
(Figure 1k and l). The tissue samples for which we had
observed blatant discrepancies, with respect to ERK phos-
phorylation in different parts of the tumor, were also
characterized by a homogeneous expression of RKIP in all
malignant cells throughout the tumor, not reflecting the
inhomogeneity of the phospho-ERK staining at all. Thus, RKIP
seems not critical for MAPK pathway inactivity in situ.
Raf kinase inhibitor protein has been described as a
metastases inhibitor in prostate cancer with loss of expression
found in metastatic tumors (Fu et al., 2003). In the analyzed
series, in only 7 of 180 samples, RKIP expression was not
detectable in a considerable subset of tumor cells (Table 1);
notably, only 2 of these sections were derived from metastatic
lesions, whereas 5 were from primary tumors. Furthermore,
we scored the RKIP staining intensity in three categories: dim,
Table 2. Frequency of positive cells in
immunohistological analysis for phospho-ERK, total
ERK, and RKIP
Frequency of positively stained cells
o1% 1–10% 10–30% 30–60% 60–90% 490%
Phospho-ERK
RGP melanomas 51% 46% 3% — — —
VGP melanomas 24% 43% 19% 2% 3% 8%
Ab E10
Metastases 80% 12% 3% 4% — 1%
All tumors 50% 30% 12% 3% 2% 5%
Phospho-ERK
RGP melanoma 54% 21% 13% 3% 3% 8%
VGP melanoma 30% 38% 16% 11% 3% 1%
Ab 20G11
Metastases 59% 14% 10% 9% 4% 3%
All tumors 46% 25% 13% 8% 3% 3%
Total ERK
Primary melanomas — — — — 10% 90%
Metastases — — — 10% — 90%
All tumors — — — 5% 5% 90%
RKIP
Primary melanomas — — — 1% 4% 95%
Metastases — — — 2% — 98%
All tumors — — — 1% 2% 97%
Ab, antibody; ERK, extracellular signal-regulated kinase; RGP, radial
growth phase; RKIP, Raf kinase inhibitor protein; VGP, vertical growth
phase.
Phospho-ERK, RKIP, and total ERK data were generated by analysis of 205,
180, and 20 individual samples, respectively. 35 RGP and 98 VGP
melanoma samples were stained for phospho-ERK.
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standard, and bright. Again, also with respect to RKIP staining
intensity, we could not detect decreased RKIP expression in
metastatic melanoma (Figure 4a).
However, comparing the intensity of RKIP staining with
the percentage of phospho-ERK-positive cells, it was statis-
tically significant (P¼0.0107 in the Kruskal–Wallis test) that
tumor tissues with strong RKIP staining harbored higher
proportions of phospho-ERK-positive cells (Figure 4b).
Neither the proportion of phospho-ERK-positive tumor cells nor
the intensity of RKIP staining correlates with the clinical course
Finally, a correlation of phospho-ERK and RKIP expression
with the clinical course of the patients was performed. We
restricted this analysis to primary melanomas, as several
metastatic lesions were obtained from individual patients, but
still displayed different staining patterns. For the analyzed
primary tumors, it should be further noted that these were all
chosen to be in the vertical growth phase to allow enough
clinical events with respect to disease progression within the
median clinical follow-up of 5 years. Thus, our analysis does
not address a potential role of these proteins during early
phases of melanomagenesis. With these restrictions in mind,
our results clearly demonstrate that neither the proportion of
phospho-ERK-positive cells (determined either with Ab E10 or
20G11) nor the intensity of RKIP staining correlated with
overall survival of the patients (Figure 5).
DISCUSSION
It was like a starter’s gun for cancer researchers around the
world when Davies et al. (2002) reported the presence of
mut (BRAF )wt (BRAF )mut (BRAF )wt (BRAF )
mut (BRAF/NRAS )wt (BRAF/NRAS ) mut (BRAF/NRAS )wt (BRAF/NRAS )
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Figure 2. The proportion of phospho-ERK-positive cells does not correlate with the presence of NRAS and BRAF mutations. Box and whiskers plot
correlating the phospho-ERK phenotype with the NRAS/BRAF genotype. The percentage of phospho-ERK-positive cells was evaluated and classified as
described under Materials and Methods. In the upper part, the mut group, which contains all tumors with validated NRAS or BRAF mutation, is compared
with BRAF/NRAS wt tumors, whereas in the lower part, the mut (BRAF) group contains all tumors with validated BRAF mutation and is compared with
the tumors without BRAF mutation. On the left, the results obtained with the antibody (Ab) E10 are depicted, whereas in the diagrams on the right, the
Ab 20G11 was used. The numbers of analyzed individual tumors in each group are indicated.
Histone H3
Phospho-ERKPhospho-ERK
NCNCNC
β-Tubulin
Phospho-ERK
β-Tubulin
A N A N A N
SK
m
el
28
M
el
2A
FM
88
SK
m
el
28
M
el
2A
FM
88
C: cytoplasmic fraction
N: nuclear fraction
A: attached
N: not attached
×106 cells1.00.50.20.121.00.50.250.121.00.50.250.12
FM88SKmel28Mel2Aa
b c
Figure 3. ERK phosphorylation is still subject to regulation in BRAF mutant
melanoma cell lines and the majority of phospho-ERK is in the cytoplasm. (a)
ERK phosphorylation is inhibited at high cell densities. The indicated BRAF
mutant cell lines were seeded in 12-well plates with the indicated cell
numbers and harvested 24hours later. Cell lysates were analyzed for the
presence of phosphorylated ERK protein by Western blot. b-Tubulin served as
a loading control. (b) ERK phosphorylation depends on cell adherence. The
BRAF mutant melanoma cell lines were cultured either in standard tissue
culture plates or in ultralow attachment plates in which adherence is inhibited
by a hydrophilic, neutrally charged hydrogel layer. (c) Cytoplasmic and
nuclear fractions of lysates of the indicated melanoma cell lines were
analyzed for the presence of phospho-ERK. Histone H3 served as nuclear
marker protein.
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activating BRAF mutations in more than 60% of their
melanoma samples and with lower frequencies in other
cancers. Since then, myriads of papers (180 are listed by the
COSMIC database, http://www.sanger.ac.uk/genetics/CGP/
cosmic/) have been published describing the detection of
BRAF mutations in different types of cancers, particularly in
melanoma. However, to date, there is no substantiated
description of the actual impact of these mutations on the
activation status of the MAP kinase pathway in melanoma
tumor tissues.
Our results suggest a regulated MAP kinase signaling in the
majority of tumor cells rather than an abundant, continuous
activation of this pathway. Moreover, we report the surprising
finding that there is no correlation between BRAF/NRAS
mutations and the ERK phosphorylation status. Similar to our
findings in malignant melanoma, a lack of association
between BRAFmutation and MAPK activation in melanocytic
nevi (Uribe et al., 2006), in papillary thyroid carcinoma (Zuo
et al., 2007), and endometrial cancer (Mizumoto et al., 2007)
has been described recently. In contrast, a correlation
between BRAF/NRAS mutation and actual MAP kinase
pathway activity in melanoma was suggested in another
paper (Ellerhorst et al., 2006). In a limited number of 20
analyzed melanoma tissues, positive phospho-ERK staining
was described in 9 of 12 melanoma samples with activating
NRAS or BRAF mutation, whereas 6 of 8 tissues without
mutation in either of these genes were negative for activated
MAPK. However, the authors did not specify what they
scored as positive staining; whether this means that some or
the majority or all cells displayed ERK phosphorylation.
Similarly, Cohen et al. (2002), who described ERK phospho-
rylation to be present in the majority of cutaneous melanoma,
did not report on the proportion of phospho-ERK-positive
tumor cells. In this study analyzing a substantial number of
primary melanomas (n¼133), a mean of 13.3 and 13.6% of
the tumor cells displayed ERK phosphorylation using two
different Abs, that is, clones E10 and 20G11, respectively.
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evaluated as dim, standard, or bright. (a) Distribution of tumor sections with
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statistically significant with P¼0.0107 in the Kruskal–Wallis test.
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Figure 5. Correlation of phospho-ERK and RKIP status with overall survival.
Kaplan–Meier plots for overall survival for primary tumors stratified for (a)
410% and o10% phospho-ERK-positive tumor cells, as analyzed with the
antibody (Ab) 20G11, (b) 410% and o10% phospho-ERK-positive tumor
cells, as analyzed with the Ab E10, and (c) the intensity of RKIP staining.
Overall survival was measured from diagnosis of primary vertical growth-
phase melanoma to time of death. In panels a, b, and c, the data from 46, 94,
and 92 patients, respectively, were included.
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Recently, Zhuang et al. (2005) described a higher proportion
of phospho-ERK-positive cells, that is, 65 and 77% of the
cells, in thin and thick melanomas, respectively, whereas
Uribe et al. (2006) reported ERK1/2 phosphorylation to be
immunohistochemically detectable in only a small fraction of
melanoma cells. Moreover, 15% of the primary tumors were
completely phospho-ERK negative. Also, in metastatic
melanoma, we observed only rarely high proportions of
phospho-ERK-positive cells, although this was recently
described by others in a limited number of tumor samples
(Mirmohammadsadegh et al., 2007).
A clear-cut observation of our study is the inhomogeneity
of ERK phosphorylation not only among, but also within,
many of the tumors analyzed. This might be due to a
multiclonal origin of the tumors, with some clones bearing an
activating BRAF mutation and displaying ERK phosphoryla-
tion, whereas other clones without mutation may be
characterized by inactivity of the MAP kinase pathway.
However, titration experiments revealed that when the
percentage of DNA heterozygous for BRAFV600E was below
20% (and thereby the mutated allele below 10%), the
mutation could not be detected any more in the sequencing
chromatogram (data not shown). For most DNA samples
derived from tumors of the analyzed series, the signal for the
mutated allele was similar to or only slightly weaker than the
wt signal (which may be due to contaminating stromal cells),
suggesting the heterozygous presence of a mutation in most
tumor cells. Therefore, the frequent cases with fewer than
10% phospho-ERK-positive cells cannot be attributed to a
multiclonal origin of the tumors in cases with verified BRAF
or NRAS mutations.
Although BRAF mutations are common also in nevi, the
high frequency of BRAF mutations in melanoma is a
substantial argument that BRAF activation plays a role at
some point in melanomagenesis. Tumor-associated BRAF
mutations generally provoke increased ERK phosphorylation
in cell culture experiments (Wan et al., 2004), and BRAF
mutant cells are particularly sensitive toward MEK inhibition
(Solit et al., 2006), suggesting that the MAP kinase pathway is
critical for the contribution of activated BRAF to tumorigen-
esis. However, the striking variation of the level of ERK
phosphorylation in different melanoma cells within a given
tumor in the majority of samples with validated BRAF
mutation suggests that even in BRAF mutant cells, signal
modulation can take place in melanoma cells downstream or
at the level of Raf. In these cases, mere technical problems,
that is, impaired staining of phospho-ERK due to depho-
sphorylation during tissue preparation, fixation artifacts, or
Ab instability, as an explanation for the low level of
phosphorylated ERK present in situ is very unlikely. Further-
more, we were able to conclusively demonstrate in vitro that
MAPK signaling is still subject to regulation in melanoma
cells, even in the presence of constitutively active BRAF: as a
response to both high cell densities and inhibition of
anchorage to the tissue culture plate, a decrease in ERK
phosphorylation in BRAF mutant melanoma cell lines was
observed. Decreased MEK and ERK phosphorylation in
confluent fibroblasts is accompanied by increased expression
of the MAP kinase phosphatases 1, 2, and 3 (Wayne et al.,
2006). However, to the best of our knowledge, otherwise, not
much is known about the signaling events involved in MAPK
pathway regulation associated with the so-called ‘‘contact
inhibition.’’ In contrast, for anchorage-dependent regulation
of ERK activity, integrin-dependent signaling involving the
cyclic nucleotide-dependent PKA (protein kinase A) and PAK
(p21-activated kinase) 1 has been implicated (Juliano et al.,
2004). Through an as yet not fully understood mechanism,
the transition of cells from an integrin anchored to the
suspension state causes changes in intracellular cAMP levels
and activation of PKA (Howe et al., 2002). Activated PKA can
phosphorylate and thereby inactivate PAK1. PAKs have been
shown to regulate signaling in the mitogenic cascade by
providing permissive phosphorylations at S338 in Raf-1,
required for Raf activation, and at S298 in MEK1, promoting
the Raf–MEK association (Dhillon et al., 2003; Slack-Davis
et al., 2003). Moreover, PKA can directly phosphorylate
several sites in Raf-1, such as S259 and S621, which both
negatively regulate Raf kinase activity (Dhillon and Kolch,
2002). The role of cAMP in regulating BRAF activity,
however, is not that clear because inactivation as well as
activation has been reported (Houslay and Kolch, 2000). A
further mechanism that has been proposed to link integrin
engagement with ERK activation in a Raf-independent
manner involves the focal adhesion kinase (Schlaepfer
et al., 1999).
In the presented immunohistochemical analysis, phos-
phorylated ERK appears to be predominantly located in the
cytoplasm of the tumor cells. This is true for both phospho-
ERK Abs used, although 20G11 more frequently displayed a
nuclear staining compared to clone E10. Because many of the
described targets of activated ERK are transcription factors
and also because nuclear translocation accompanies phos-
phorylation of ERK upon stimulation of resting cells (Kondoh
et al., 2005), the staining pattern observed with 20G11 is
more likely to reflect the real subcellular distribution,
suggesting that E10 somehow is impaired in its ability to get
access to its target when located in the nucleus. Conversely,
phosphorylation of ERK takes place in the cytoplasm at the
plasma membrane and activated ERK is known to phosphor-
ylate several proteins located in the cytoplasm and even
mitochondrial targets of phospho-ERK have been described
(Lewis et al., 1998; Chen et al., 2001). Moreover, subcellular
distribution of ERK has been reported not necessarily to
depend on the phosphorylation state. On EGF or NGF
treatment of PC12 cells, for example, ERK protein is
transiently translocated to the nucleus but rapidly returns to
the cytoplasm. This is accompanied by dephosphorylation of
ERK. However, when dephosphorylation is inhibited by
phosphatase inhibitors, the relocation to the cytoplasm takes
place as well (Horgan and Stork, 2003). A similar situation
may result when ERK is permanently re-phosphorylated
owing to activating mutations in the MAPK pathway.
Subcellular localization of ERK is believed to depend largely
on scaffold proteins, and a number of scaffolds and anchor
proteins like PEA-15, arrestin, and Sef have been described to
be capable of targeting phosphorylated ERK to distinct
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cytoplasmic sites (Caunt et al., 2006; Sacks, 2006). Notably,
by means of subcellular fractionation, we demonstrated that
in melanoma cells in vitro, under steady-state conditions, the
majority of phospho-ERK is indeed located in the cytoplasm.
The RKIP was shown to block both NF-kB pathway and
MAP kinase signaling (Odabaei et al., 2004). RKIP over-
expression interferes with downstream events such as
activation of ERK and induction of AP-1-dependent reporter
genes and oncogenic transformation elicited by activated
CRAF (Yeung et al., 1999) or BRAF kinase (Park et al., 2005).
Therefore, we speculated whether RKIP might be causative
for MAPK pathway silencing in those melanoma cells with
absent ERK phosphorylation. The homogeneous expression of
RKIP in virtually all melanoma tissues examined irrespective
of ERK phosphorylation, however, strongly argues against a
critical role for RKIP in MAPK pathway silencing in
melanoma. Furthermore, high-intensity RKIP staining corre-
lated with increased ERK phosphorylation. This paradoxical
observation has already been reported for breast cancer,
which has led these authors to speculate that RKIP function in
breast cancer is not exerted by blocking the MAP kinase
pathway (Hagan et al., 2005).
In prostate cancer, RKIP was described as a metastases
suppressor, which does not influence the tumorigenic
properties of prostate cancer cells per se, but which rather
decreases metastases formation (Fu et al., 2003). In line with
this function as a metastases suppressor, expression was
shown to be reduced in metastatic lesions compared to
primary tumors in prostate and also in breast cancer (Fu et al.,
2003; Hagan et al., 2005). Recently, it was suggested that
RKIP might also act in melanoma as a metastases suppressor
as well. By immunohistochemical analysis in a limited
number of nevi (n¼ 5, completely positive), primary (n¼ 5,
focally negative), and metastatic melanoma (n¼ 5, comple-
tely negative), a decline in RKIP expression during progres-
sion of melanocytic lesions was demonstrated (Schuierer
et al., 2004). In our studies addressing a larger series,
however, we observed a general and—compared to stromal
cells—high expression of RKIP in primary as well as in
metastatic melanoma.
Conclusion
In this study, we demonstrate that ERK is activated in only a
minority of melanoma cells in primary tumors and metastatic
lesions. This suggests that MAPK pathway signaling may be
important only in distinct subsets of tumor cells. As ERK
phosphorylation showed no correlation to the presence of
activating BRAF mutations, the way in which activated BRAF
contributes to melanomagenesis may be more complex than
previously anticipated. This notion has important implica-
tions for therapeutic approaches targeting the MAP kinase
pathway.
MATERIALS AND METHODS
Tumor material and evaluation of the mutational BRAF/NRAS
status
Paraffin-embedded tumor samples from primary and metastatic
melanomas were obtained by surgical excision. All tumors had
undergone routine histology for diagnosis. The three immediately
following slides from the blocks were used for DNA extraction, and
the following slides were used to confirm the presence of the lesion
and for IHC. Before DNA extraction, adjacent normal tissue was
macroscopically dissected. PCR amplification and sequencing of
BRAF exons 11 and 15 and NRAS exons 1 and 2 were performed as
described (Houben et al., 2004). Informed consent was obtained
from all patients before any of these measures, and the study was
performed in adherence to the Declaration of Helsinki Principles.
The medical ethics committee of the Universita¨tsklinik Wu¨rzburg
approved all described studies.
Immunohistochemistry
Sections (3 mm) of paraffin-embedded tumors were dried at 56 1C and
then treated two times with xylol for 10minutes at room
temperature. Subsequently, sections were washed twice with
absolute ethanol and two times with 70% ethanol followed by one
rinse with bidistilled water. For antigen retrieval, sections were
incubated with citrate buffer (Dako, Hamburg, Germany), pH 6.0
(phosphorylated ERK) or pH 9.0 (RKIP and total ERK), for 10minutes
at 90 1C and rinsed with bidistilled water. Next, slides were rinsed
twice with phosphate-buffered saline (PBS; Dako, S3024) and
thereafter incubated with Blocking Solution (Dako, S2023) for
10minutes at room temperature. After two additional washing steps
with PBS for 10minutes at room temperature, the mAb clones E10
and 20G11 targeting phospho-p44/42 MAP kinase (Thr202/Tyr204)
(Cell Signaling Technology) or the polyclonal Abs a-RKIP (Upstate,
Charlottesville, VA) and a-p44/42 MAP kinase (Cell Signaling
Technology) were added to the sections in PBS, followed by an
overnight incubation at 4 1C. After two 10minute washes in PBS,
biotinylated multispecies-specific secondary Ab (Dako, K5003) was
added to the sections for 30minutes at room temperature. Slides
were then washed twice in PBS/BSA, and bound Abs were visualized
using streptavidin–HRP (Dako, K5003) and Vector Vip (Vector
Laboratories, Burlingame, CA) as peroxidase substrate according to
the manufacturer’s guidelines. Finally, the nuclei were stained with
hemalaun.
Evaluation of immunostaining
By visual inspection, all slides were examined and scored by two
individual persons. The intensity of staining was scored as dim,
standard, or bright, and the subcellular localization in nucleus and/
or cytoplasm was recorded. Moreover, the percentage of positively
stained tumor cells was evaluated and classified as (a) below 1%, (b)
1–10%, (c) 10–30%, (d) 30–60%, (e) 60–90%, or (f) more than 90%.
For statistical analysis, the tumors in group (a) were set to 0%, in (b)
to 5%, in (c) to 20%, in (d) to 45%, in (e) to 75%, and in (f) to 95%.
Statistical analysis was performed using the programs GraphPad
Instat and GraphPad Prism.
Melanoma cell lines and Western blot analysis
The melanoma cell lines Mel2A, Skmel28, and FM88 were grown in
RPMI 1640 (10% fetal calf serum). Sequencing as well as application
of real-time PCR-based assay for the detection of BRAF mutation
(Houben et al., 2006) demonstrated that Mel2A cells are hetero-
zygous and Skmel28 are homo- or hemizygous for BRAFV600E,
whereas FM88 are homo -or hemizygous for BRAFV600K. For protein
analysis, cells were seeded with the indicated cell number in 12-well
2010 Journal of Investigative Dermatology (2008), Volume 128
R Houben et al.
Phospho-ERK Staining in Human Melanoma
plates or in ultralow attachment plates (Corning, Corning, NY), and
after 24 hour incubation, they were lysed on ice using Laemmli
buffer. For subcellular fractionation, cells were lysed in a buffer
preserving intact nuclei (10mM HEPES (4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid), pH 7.9, 1.5mM MgCl2, 10mM KCl, 1%
Triton X-100, 0.5mM DTT (dithiothreitol)) (Nilsson and Landberg,
2006), kept on ice for 10minutes, and centrifuged at 10,000 g at 4 1C
for 10minutes. The supernatants (cytoplasmic fractions) were stored,
and the pellets were resuspended in high-salt buffer (10mM HEPES,
pH 7.9, 400mM NaCl, 0.1mM EDTA, 5% glycerol, 0.5mM DTT),
kept on ice for 20minutes, and centrifuged at 10,000 g at 4 1C for
10minutes. The supernatant (nuclear fraction) and the cytoplasmic
fraction were then reduced by boiling with Laemmli buffer.
Cell lysates were resolved by SDS-PAGE and transferred to
nitrocellulose membranes. After being blocked for 1 hour with PBS
containing 0.05% Tween 20 and 5% powdered skim milk, blots
were incubated for 2 hours or overnight with the primary Ab, washed
three times with PBS with 0.05% Tween 20, and then incubated with
a peroxidase-coupled secondary Ab. After extensive washing, the
bands were detected using a chemiluminescence detection kit
(Roche Diagnostics, Mannheim, Germany). The mAbs a-phospho-
p44/42 MAP kinase (Thr202/Tyr204) (clone E10; Cell Signaling
Technology) and a-b-tubulin (Sigma, Ottobrunn, Germany) were used.
Survival analysis
The patient cohort used for the correlation of immunostaining and
overall survival of the patients included those for which a tissue
section of a vertical growth phase melanoma was successfully
stained by IHC. The median age at diagnosis of the analyzed patients
was 61 years (range 24–89 years), and the cohort included 49 men
and 47 women. Kaplan–Meier plots for overall survival were charted
using the program GraphPad Prism. As staining was not evaluable in
some cases, some survival curves represent a reduced number of
patients (indicated in the figure legend). For evaluation of
significance, the log rank (Mantel–Cox) test was performed.
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